Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222572 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01222572: Clinical Trial Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT01222572 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222572, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects the participant experiences; the goal is to improve the likelihood of killing the tumor.
Primary Outcome
The MTD is determined by the number of patients who experience a dose limiting toxicity (DLT). The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached. DLTs were defined as follows (CTCAE v4.0): Grade 2 non-hematologic toxicities: Myelitis; Esophageal fistula, perforation, hemorrhage Grade 3 non-hematologic toxicities considered to be a direct result of therapy: Radiation pneumonitis; Pericarditis, per
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- RADIATION Stereotactic boost
- RADIATION Conventional RT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Why NCT01222572 stopped before completion
NCT01222572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT01222572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01222572 about?
NCT01222572 is a clinical study titled "Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer". In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly inc...
What is the current status of trial NCT01222572?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01222572?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Stereotactic boost (RADIATION), Conventional RT (RADIATION).
Who is sponsoring clinical trial NCT01222572?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01222572's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia